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A nuclear chocolate box: the periodic table of 
nuclear medicine. 
P. J. Blowera 
Radioisotopes of elements from all parts of the periodic table find both clinical and research 
applications in radionuclide molecular imaging and therapy (nuclear medicine). This article 
provides an overview of these applications in relation to both the radiological properties of the 
radionuclides and the chemical properties of the elements, indicating past successes, current 
applications and future opportunities and challenges for inorganic chemistry. 
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Introduction 
Since the first experimental use of the beta-emitting cyclotron-produced radionuclide phoshorus-32 for treatment of patients with 
haematological disease in the 1930s, the use of radioisotopes in medicine has expanded into a mainstream clinical speciality 
incorporating both diagnostic imaging (exploiting the tissue penetration of gamma rays derived from nuclear decay or positron 
annihilation) and targeted therapy (exploiting the cellular toxicity of non-penetrating alpha and beta particles and secondary 
electrons). Via landmark steps including clinical use of iodine-131 for therapy and diagnosis of thyroid disease, and key technologies 
such as the Anger gamma camera and, later, single-photon emission tomography (SPET), the technetium-99m generator, positron 
emission tomography (PET) and medical cyclotrons, radioisotope imaging has evolved into today’s set of cutting-edge technologies 
with applications and instrumentation dedicated not only to clinical medicine but to basic biomedical and preclinical research. Over 
this time the range of available radioisotopes, produced by cyclotrons, nuclear reactors and generators, has grown and now represents 
all areas of the periodic table with applications that have evolved to make best use of both the radiological (half-life, specific activity 
and of course emission type – alpha, beta, gamma, positron, Auger electron, and even associated Cerenkov light emission) and 
chemical properties (biological behaviour and chemical suitability for incorporation into complex targeting molecules and 
bioconjugates) of the radioelement for the biomedical purpose at hand. This article presents a survey of the variety of these properties 
and their uses, linking properties to applications and briefly reporting on current developments and future challenges for inorganic 
chemists in this field, using the Periodic Table (Fig. 1) – the “nuclear chocolate box”, from which selections can be made to suit a 
variety of different needs - as a basis of classification. In this way it is hoped that the article will provide a map for navigation of 
radionuclide imaging and therapy specifically for inorganic chemists. It should indicate of the role of the inorganic chemist, who 
must partner with biologists, clinicians, physicists, pharmacologists, radiochemists and other specialists to move forward in this 
highly multidisciplinary field. The material is arranged roughly by periodic group, with some flexibility in this approach to allow 
for parallels in applications to be grouped together where this is appropriate; lanthanides and actinides are accorded the status of 
“honorary groups” rather than periods for this purpose. Only elements that have radioisotopes with a significant current or promising 
clinical or research application are included; some groups offer greater riches in this respect than others. Elements of particularly 
current topical interest are considered in somewhat more detail. 
 
Figure 1:  Periodic table highlighting (shaded) elements with radionuclides with uses or identified potential uses in molecular imaging or targeted radionuclide therapy. 
Main uses are identified by symbols: g (gamma camera imaging/SPET), b+ (positron emission tomography) and T (therapy, using beta-, alpha, or Auger-emitting 
radioisotopes). Some unshaded elements also have indirect importance e.g. as parent radionuclides for directly-used radionuclides, or as cyclotron target materials, or 
chemical binding sites for biomolecule labelling, hence the “usefulness” is somewhat arbitrary. 
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Group 1 
In group 1, only rubidium offers an imaging radioisotope with a significant biomedical application – the short half-life positron 
emitter 82Rb (b+, 95%, half-life 75 s). As a group 1 metal whose chemical speciation under biological conditions is almost completely 
restricted to the hydrated cation, its potential for incorporation into complex targeting molecules is negligible. Nevertheless, its 
periodic position underlies its application; Rb+ is a potassium mimic and its ionic radius, despite being larger than that of K+, does 
not prevent it serving as a substrate, in place of K+, for the Na+/K+-ATPase, a ubiquitous antiporter in cell plasma membranes that 
pumps potassium ions into cells and sodium ions out, in the ratio 2:3, driven by and coupled to the hydrolysis of ATP. This pump is 
most abundant and active in the myocardium, resulting in 82Rb+ that has been delivered to the heart via blood becoming trapped 
rapidly in the myocardium, provided blood flow is adequate to deliver it and the tissue is sufficiently metabolically active and 
energetic to drive the pump. Images of the distribution in the myocardium, obtained by PET, provide a map of its perfusion, giving 
valuable information about the patient’s condition for the cardiologist.1 An example is shown in Fig. 2.  
 
Figure 2:  Top: Example of myocardial perfusion PET imaging using 82Rb+ (transverse (top) and sagittal (bottom) sections); bottom: PET-CT scan (transverse section, 
pelvic region) of a patient with colorectal cancer after injection of 82Rb+. (Images courtesy of Prof A. M. Groves, University College London Hospitals)  
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The excellent utility of this radioisotope for this purpose arises from its high-abundance positron emission, and its availability from 
a convenient generator in which the parent isotope is strontium-82 (half-life 25 days), adsorbed on a solid phase such as stannic 
oxide, decays to 82Rb which is eluted with physiological saline. Because of the 75 s half-life, there is not time for manipulation with 
syringes or procedures for radiolabelling or sterilisation, and the generator is “plumbed” directly into the vein of the subject via an 
infusion set. The short half-life allows repeated administration and imaging after a short interval, while keeping the radiation dose 
to the patient low. Although costly, this is now a commonplace procedure especially in the US.  
 
Myocardial perfusion scanning using the 82Rb-generator relies on the same biochemical principle as the older (>30 years) use of 
monovalent thallium-201 (gamma-emitter), which is also a potassium mimic, for obtaining similar clinical diagnostic information 
with a gamma camera (see Group 13).  201Tl+ scanning has also been applied in the past to tumour imaging, relying on the same 
biochemical pathway, suggesting that application of 82Rb could be extended in the same way. Accordingly, a recent evaluation in 
patients with colorectal and lung cancer confirmed tumour avidity of the tracer and the ability to map tumour perfusion (Fig. 2),2 
opening up a new clinical field of application for this radionuclide. 
Group 2 
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Like the group 1 elements, the group 2 metals are not amenable to kinetically stable incorporation into molecules and bioconjugates, 
and their radioisotopes find their application mainly through mimicry of calcium. Thus the beta emitter strontium-89 (half-life 53 
days) has been used for many years as a palliative therapy for painful bone metastases in cancer, especially prostate cancer, by 
exploiting toxicity of the beta emissions, most likely towards inflammatory cells in these lesions. After intravenous administration 
of 89SrCl2, the strontium is transported in way that, to an extent, mimics calcium and it accumulates in sites of active bone mineral 
deposition (rather than mineral lysis, as found in for example multiple myeloma bone lesions) found in such metastases, leading to 
higher radiation doses in these tumours than in normal tissues.3 89Sr has no positron or gamma emissions and so is not amenable to 
high quality quantitative imaging, but the positron emitter 83Sr (β+, 24%, half-life 33 h) which is produced by proton irradiation of 
85Rb in a cyclotron,4 or the gamma emitter 85Sr (g, 100%, half-life 65 days) can in principle be used to determine its quantitative 
biodistribution.  
 
The other group 2 radionuclide of major importance emerging recently is radium-223 (a, 94%, half life 11.4 days), an alpha emitter, 
which also mimics calcium in accumulating selectively in sites of bone mineralisation (Fig. 3). The recent success of clinical trials 
of 223RaCl2 in patients with metastatic prostate cancer represents the first major application of alpha emitting isotopes in humans. It 
is a significant step forward in therapeutic nuclear medicine opening the door to wider use of alpha-emitter therapy in other cancers.  
 
Figure 3:  Biodistribution of 223Ra in a patient with metastatic prostate cancer after i.v. administration of 223RaCl2.5 The anterior (left) and posterior (right) views show 
specific uptake in the sites of bone metastases indicated by the 99mTc bone scan (M), and activity in the gut (G) indicating radioactivity that has undergone hepatobiliary 
excretion. The gamma camera image was possible by virtue of a low abundance gamma emission from 223Ra accompanying the alpha decay. (Adapted with permission 
from ref. 5). 
 
 
 
Applications of these therapeutic isotopes in other cancers will require their incorporation into more complex targeting molecules, 
which is extremely challenging for the group 2 metals as they do not readily form kinetically stable chelates; indeed, the development 
of novel chemistry to incorporate these metals into bioconjugates with a degree of kinetic stability might be considered a challenge 
to inorganic chemists. The insoluble nature of many of their salts, including minerals such as hydroxyapatite, may offer the possibility 
of incorporating them into inorganic nanoparticles. These could then be targeted by derivatising their surface using conjugates of 
targeting biomolecules with phosphonates and bisphosphonates, which form stable links with the surface of such nanoparticulate 
materials.6 
Group 3 
99mTc bone scan 
  
223Ra 
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While the basis of the uses of the group 1 and 2 elements is restricted to mimicry of the biological behaviour of their biologically 
important congeners (namely potassium and calcium), from group 3 onwards there is opportunity to incorporate the radioelement 
into more complex molecules and bioconjugates for targeted molecular imaging, by chelation or covalent bond formation. From a 
historical perspective the Group 3 elements are not an ideal starting point since the groundwork for their applications was laid in 
past decades using related trivalent metals from other parts of the periodic table, especially Group 13 and lanthanides (vide infra). 
The trivalent, “hard” metal ions from these groups find their main applications as radiolabels for biomolecules, incorporated with 
use of bifunctional chelators (Fig. 4) which share, to an extent, common design features but with subtle variations to suit individual 
metals. These are discussed in more detail in their respective sections and have recently been much more comprehensively reviewed 
elsewhere.7  
 
Group 3 is represented by scandium-44 (b+, 94%, half-life 3.97 h), yttrium-90 (b-, 100%, half-life 64 h) and yttrium-86 (b+, 33%, 
half life 14.7 h). 44Sc is a recent innovation,8 available through development of the 44Ti/44Sc generator and offering the possibility, 
after further development, of a PET radionuclide chemically similar to gallium-68 (vide infra) but for applications requiring a 
somewhat longer half-life (3.97 h c.f. 68 min). The 44Ti parent has a long half-life of 60 years, which raises problems with radioactive 
waste management. There is potential for a “theranostic” (PET imaging/radionuclide therapy) pair by using it alongside the potential 
therapeutic radionuclide 47Sc (b-, 100%, half-life 3.35 days).9 DOTA-based chelators (1, Fig. 4) have been employed to link it to 
targeting biomolecules. 
 
90Y is a pure high-energy (2.28 MeV) beta-emitting radionuclide that has growing applications in radionuclide therapy when coupled 
to small tumour-targeting peptides and monoclonal antibodies. Its beta emissions have a relatively longer range - about a centimetre 
in tissue - compared to other therapeutic beta emitters such as 131I and 177Lu. Most prominent currently among the targeting molecules 
used are the somatostatin analogues, used for radionuclide therapy of neuroendocrine and other tumours that express somatostatin 
receptors,10 and the antibody-based treatment Zevalin for lymphoma.11 The yttrium is coupled to the targeting peptide or antibody 
by means of a bifunctional chelator with amine and carboxylate donors, such as the macrocyclic DOTA and non-cyclic CHX-A′′-
diethylenetriaminepentaacetic acid (2), Fig. 4 (vide infra). Since 90Y has no positron or gamma emissions, quantification of its 
biodistribution by imaging to assess radiation doses is difficult, and analogues labelled with the gamma-emitter indium-111 have 
been used as surrogates for this purpose. Inorganic chemists will recognise that this poses uncertainties because the coordination 
chemistry of indium and yttrium is subtly different and can (and does) lead to differences in biodistribution and clearance. Therefore 
to obtain definitive and quantitative biodistribution information to underpin radionuclide therapy, the positron emitting isotope 86Y, 
which can be produced on many biomedical cyclotrons, can be used.12 
 
Figure 4:  Structures of bifunctional chelators used for radioactive di-, tri- and tetravalent metal ions  
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Group 4 
Zirconium-89 (b+, 23%, half-life 78.4 h) is a rising star in Group 4, emerging in response to the need for a longer half-life positron 
emitter to match the growth in availability of PET scanners in the last decade. 89Zr is quickly becoming the PET replacement for the 
gamma-emitter indium-111 (see Group 13), which, with its half-life of 67.3 h, has been the radioisotope of choice since the 1980’s 
for labelling molecules with slow pharmacokinetics, i.e. mainly monoclonal antibodies. IgG antibodies clear very slowly from blood 
and continue to accumulate in tumour targets and improve target-to-background ratios over a period of several days. Consequently 
a relatively long half-life is required, and imaging is typically carried out 24-72 h after injection of the tracer. The improvements in 
image sensitivity and quantification offered by PET compared to SPET have created a desire for a radionuclide with similar 
chemistry (i.e. amenability to kinetically stable chelation) and radiological half-life. Despite some disadvantages (low positron yield, 
abundant high-energy gamma emissions, both of which lead to concerns about high patient radiation dose), 89Zr fits this need. This 
presents a new challenge for inorganic chemists: new chelators are needed that impart both kinetic stability and efficient, mild 
labelling that overcomes the tendency towards hydrolysis in higher pH conditions, while fundamental studies of the coordination 
preferences of Zr4+ are less complete than is the case for some other metals described in this article. A number of bifunctional 
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chelators conventionally used with the trivalent metals (see Group 13; Fig. 5), such as DOTA and DTPA derivatives were evaluated 
without great success but, somewhat fortuitously, the iron chelator desferrioxamine-B (DFO, 3, Fig. 4) proved to combine the most 
efficient labelling with the best long-term in vivo stability, despite the general acceptance of DFO as a ligand for hard trivalent metals 
rather than tetravalent ones such as Zr4+, and despite the fact that it cannot satisfy the evident preference shown by zirconium for 
coordination numbers greater than 6 (Fig. 5).13 Zr4+ readily transchelates from the oxalate complex [Zr(oxalate)4]4-  (the form in 
which is it most often purified from the yttrium target after proton irradiation in the cyclotron) to form the DFO complex under mild 
conditions. Antibodies labelled with 89Zr through conjugation with DFO allow imaging for several days, in both experimental 
animals and humans, with very little loss of 89Zr (which is manifested in uptake in the bones and joints, as exemplified in Fig. 6). 
This has made possible the use of 89Zr-PET to evaluate the biodistribution in humans of several candidate antibody therapeutics,13-
16 and to demonstrate the advantages of 89Zr-PET over SPET (even with the optimal SPET isotope 99mTc), for example in sentinel 
lymph node imaging in humans.17 Efforts are in progress to develop ligands with superior Zr4+ chelation properties compared to 
DFO, including the tripodal tris(hydroxypyridinone) hexadentate chelator YM10318 (4, Fig. 4) developed for use with gallium-68.19 
A promising strategy is represented by octadentate designs based on a tetrapodal array of four bidentate oxygen donor ligands.20, 21 
The structure of the Zr4+ tetrakis(N-methylacetohydroxamate) complex, which has a 4:1 ligand:metal stoichiometry forming a 
mononuclear eight-coordinate structure22 (Fig. 5), suggests that an assembly of four such bidentate ligands is the ideal way to meet 
the coordination preferences of zirconium. It has been most conveniently and elegantly implemented by linearly extending the DFO 
ligand to include a fourth hydroxamate group, producing an octadentate ligand 13 that on (very preliminary) evaluation appears to 
have the expected advantages over DFO itself23 (Fig. 5). This is a highly topical endeavour in radiometal chemistry; nevertheless, it 
should be recognised that, meanwhile, DFO itself is an extremely effective chelator (Fig. 6), with only slight translocation of 
radioactivity from labelled antibody to bone allowing high-quality PET imaging to be continued clinically. 
 
Another application, of growing importance, that calls for a long half-life positron emitter is radiolabelling of living cells for tracking 
their migration through the body over a period of several days. This has been a major role for the gamma-emitter 111In (see Group 
13) for more than three decades, but the advantages of PET over SPET stimulated a search for positron-emitting analogues. Despite 
the difference in preferred oxidations state, there are parallels in chemical behaviour that provide a rationale for design of such 
tracers. Thus, by analogy with the metastable lipophilic complex [InL3] (L = bidentate uninegative ligand such as oxinate and 
tropolonate, Fig. 7), which non-specifically diffuses into cells and dissociates allowing the released In3+ to bind to intracellular 
macromolecules, Zr4+ forms metastable lipophilic complexes [ZrL4] which behave similarly. The 89Zr oxinate complex has shown 
great promise in labelling a range of cell types, giving, in addition to the imaging advantages of 89Zr over 111In, equivalent cell 
labelling yields, better cellular retention of radioactivity and lower toxicity in vivo than 111In. Cancer cell migration has been followed 
for up to 14 days in a mouse model of multiple myeloma using this tracer (Fig. 7).24 
 
 
Figure 5: Left: Modelled coordination of Zr4+ by DFO (11);20 Centre: Schematic structure of ZrL4 (HL = N-methylacetohydroxamic acid) (12), serving as a template for the 
design of new octadentate chelators  for Zr+ (note that disorder in the C and N orientations of the hydroxamate rings precludes determination of their preferred relative 
orientation and suggests that any such preferences are weak);22 Right: Schematic structure of Zr4+ complex 13 of an octadentate DFO homologue.23  
 
 
 
 
 
 
 
Figure 6: PET images showing biodistribution of 89Zr-oxalate complex (top) and 89Zr-labelled trastuzumab-DFO conjugate (bottom) at 1 h (left) and 4 h (right) post-
injection in mice. Oxalate complex is gradually cleared from blood to bone and to some extent excreted through kidney, while the labelled antibody remains largely in 
the blood pool until at least 24 h, with only slight uptake in bone by 24 h. 
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Figure 7:  PET/CT scans comparing cell tracking with 111In(oxinate)3 (top) and 89Zr(oxinate)4 (bottom) labelled myeloma cells in mice. Cells initially accumulate in lungs, 
followed by migration to spleen, liver and bone marrow. Less uptake in kidney is observed for 89Zr, suggesting greater stability and cell survival.24 
89Zr-herceptin,	1	h 89Zr-herceptin,	24	h 
89Zr-oxalate,	1	h 89Zr-oxalate,	24	h 
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Group 5 
Very recently niobium-90 (b+, 53%, half-life 14.6 h) has emerged as a promising radionuclide for positron emission tomography 
(PET). To date, although it can be attached to monoclonal antibodies using the bifunctional chelator DFO, limitations in the 
separation chemistry have impeded attempts at exploring the radiochemistry and imaging potential.25 Tantalum-178 (g, half−life 9.3 
min) is generated and concentrated on site as needed from W−178 (half−life 21.7 days) using a semi−automated generator system 
to maximise consistency.26 Its chemistry has not been developed for specific targeting applications. 
Group 6 
Chromium-51 (g, 9.9%, half-life 27.8 days) emits gamma rays of too high energy, and has too long a half life, for imaging 
applications but is used in nuclear medicine for non-imaging tracer applications. Molybdenum-99 and tungsten-188 are indirectly 
important as parent isotopes for technetium-99m and rhenium-188 (see Group 7). 
Group 7 
Manganese-52m (b+, 98.3%, half-life 21.1 min) can be produced from the 52Fe/52mMn generator, and in unchelated form (most likely 
Mn2+) is rapidly taken up in the myocardium and is a potential myocardial perfusion agent.27 However, it has not been adopted in 
clinical use. 
 
Technetium-99m (g, 90%, half-life 6.02 h) has for several decades been the radioisotope used in the largest number of clinical 
radionuclide scans, and the invention of the 99mTc generator, enabling daily availability of radiopharmaceuticals in all major 
hospitals, was one of the key steps in the evolution of nuclear medicine as a routine service. The generator overcomes the problem 
of worldwide distribution of the short half-life (6 h) radionuclide, by enabling it to be shipped in the form of its parent radionuclide 
89Zr%30%min% 89Zr%2%h% 89Zr%1%day% 89Zr%7%day%
111In%30%min% 111In%2%h% 111In%1%day% 111In%7%day%
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molybdenum-99 (half-life 60 h), as molybdate bound to an alumina stationary phase. Upon decay of 99Mo, [99mTc]-pertechnetate is 
formed and can be eluted from the stationary phase with physiological saline. The chemistry of technetium is so diverse, and its 
importance to nuclear medicine so great (because of the generator availability, because the single gamma photopeak at 141 KeV 
offers a close to ideal balance of attenuation and gamma camera sensitivity and resolution, and because many complexes can be 
synthesised by a simple one-step “kit” process) that it would warrant a Dalton Discussion to itself. Therefore, after a brief historical 
summary, this section will focus on the most current and topical developments.  
 
Figure 8:  A selection of established 99mTc radiopharmaceuticals and core structures (if known):  TcMDP (14), Tc(V)DMSA (15), TcDMSA (16), TcDTPA (17), TcHIDA (18) 
TcMAG3 (19), Tc(V)-nitridobis(dithiocarbamate) (20), Tc(I)-tricarbonyl (21), Tc(I)-hexakis(isonitrile) (22), Tc(V)-hynic (23), Tc(VII)-trioxo (24), and Tc(V)-dioxo (25).  
Structures of 15, 19, 20, 21, 22, 24 and 25 are known and well defined; the others are not clearly defined. 
 
 
 
Early implementation of 99mTc radiopharmaceuticals (1970s) was based on empirical biological evaluation of a variety of 99mTc 
chelates, with ligands such as dithiolates, bisphosphonates and amino- and hydroxyl-carboxylates, without guidance from the 
detailed knowledge of technetium coordination chemistry that is available today. This led to the first generation of 99mTc 
radiopharmaceuticals, many of which are still in routine use today (e.g. 99mTc-MDP (14), 99mTc-DMSA (15, 16), 99mTc-DTPA (17), 
99mTc-HIDA (18), Fig. 8) for imaging bone disease, kidney perfusion, kidney function and liver function, respectively) despite lack 
of full understanding of their structure and mechanism. In the 1980s, a more design-and-mechanism based approach began to emerge, 
informed by a growing knowledge of the coordination and oxidation state preferences of technetium. This led to a range of 
technetium “cores” – stable metal complex units that could be modified to control pharmacokinetic and targeting properties, without 
loss of control of the technetium coordination sphere. This was the basis for the second generation of 99mTc tracers which include 
well-defined compounds such as lipophilic cations for myocardial perfusion imaging (99mTc-sestamibi, 99mTc-tetrofosmin)28 and 
uncharged metastable lipophilic complexes capable of crossing the blood-brain barrier and cell-labelling (99mTc-HMPAO,29, 30 99mTc-
NOET31). In these, the biological behaviour is a consequence of the physicochemical properties of the complex such as charge, 
protic equilibria, lipophilicity, size, kinetic stability and reactivity, and possible redox reactivity. The development of a set of 
technetium cores32 including TcO3+ (e.g. 19),33, 34 TcN2+ (e.g. 20),35 Tc(CO)33+ (e.g. 21),36, 37 Tc(CNR)6+ (e.g. 22),38 Tc(hynic)3+ (e.g. 
23),39 etc., see Fig. 9) with well-defined coordination chemistry also laid the foundation for the incorporation of 99mTc into 
bioconjugates such as peptides and antibodies, and conjugates with small molecules and nanoparticles. Most current work is based 
on these established cores – there is rather little recent literature reporting new cores; one interesting recent example is the Tc(VII) 
core TcO3+ (e.g. 24), to which the 3+1 cycloaddition of alkenes offers a potential new route to bioconjugation of 99mTc40, 41 (Fig. 8).  
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Despite the historical importance of 99mTc to nuclear medicine, the nuclear medicine community is approaching something of a 
crossroads in the development of technetium chemistry, and decisions will have to be made about how to, and indeed whether to, 
make its future secure. The world’s supply of the parent isotope 99Mo emanates from a small number of aging nuclear reactors, some 
of which have recently closed temporarily for planned refurbishment or unplanned repairs, during which 99mTc was in short supply 
and nuclear medicine departments resorted to alternatives (such as [201Tl]-TlCl for myocardial perfusion imaging (see Group 13) 
and [18F]-fluoride for bone metastases. This situation will inevitably repeat itself and the future unlimited availability of 99mTc cannot 
be assured without new investment – either in new reactors to produce more 99Mo, or in development of alternative methods (e.g. 
cyclotron methods) to produce 99Mo, or cyclotron routes to produce 99mTc directly.42 Given that the overriding advantage of 99mTc 
as the most widely used radioisotope in nuclear medicine is the 99Mo/99mTc generator, cyclotron production of 99mTc has limited 
appeal because of distribution problems. At a time when PET is rapidly growing and the gallium-68 generator is set to make PET 
more widely accessible (see Group 13), perhaps even (to stretch a point) allowing 68Ga PET to supplant 99mTc SPET as the workhorse 
of nuclear medicine, there are some hard decisions to be made in the near future. 
 
Despite the present uncertainty, there is some innovation in 99mTc chemistry currently taking place. The main current challenges 
being addressed are improving the efficiency of bioconjugate labelling and the quality (homogeneity, specific activity, in vivo 
stability, target affinity) of the labelled product, and producing radiotracers for combined modality imaging (e.g. SPET/MRI, 
SPET/optical) for use with the emerging generation of combined modality scanners. One of the key attributes of 99mTc that has led 
to its predominance is the ability to synthesise a range of complexes in a one-pot, one-step process whereby [99mTc]-pertechnetate 
in saline (generator eluate) is simply added to a “kit” vial containing the necessary reducing agent, ligand and other constituents 
required to produce the desired radiopharmaceutical without need for purification or other subsequent processing. This simplicity 
means that many sterile 99mTc radiopharmaceuticals can be produced daily with minimal technologist input or costly equipment. 
While this is well-established for the “first generation” radiopharmaceuticals referred to above, the development of targeted 99mTc 
bioconjugates has not yet reached this level of simplicity. Until it does, these “third generation” 99mTc-labelled biomolecular imaging 
agents will not be routinely available to maximally benefit patients. The current most popular cores for bioconjugate labelling include 
Tc(hynic)3+, TcO3+, and Tc(CO)3+. All have limitations at present. Hynic is a bifunctional chelator that provides reasonably stable 
links to biomolecules, very efficiently at very low concentration, via one-step labelling, with high specific activity, at room 
temperature. However, while its coordination chemistry is better understood than when first introduced,39, 43 it is subject to exchange 
of co-ligands giving rise to mixtures of subtly different bioconjugates and potential co-ligand exchange in vivo. The ideal 
accompanying ligand to remedy these limitations (replacing tricine, ethylenediamine diacetic acid, water-soluble phosphines etc.) 
has yet to be introduced. The TcO3+ core can be linked to biomolecules by a variety of nitrogen- and sulfur-donor polydentate ligands 
such as mercaptoacetyl triglycine (MAG3, 19),44 1,4,8,11-tetraaminododecane (25),45, 46 dimercaptosuccinic acid (15)47 etc.  (Fig. 
8). These are highly stable but none have been developed into a simple, mild one-step labelling process. The Tc(I) tricarbonyl core 
Tc(CO)3+ has been the subject of much attention and application, for labelling a range of small molecules, peptides and especially 
for radiolabelling proteins incorporating a histidine tag (a sequence of histidines first developed as a motif to assist protein 
purification during biological production). The labelling procedure requires first the synthesis of the putative intermediate 
[99mTc(CO)3(H2O)3]+,37 which is then incubated with the His-tagged protein producing a highly stable conjugate in which the 
technetium is coordinated by at least two imidazole groups of histidine residues. Recently, attempts have been made to place this 
bioconjugation step on a more efficient footing, by modifying the design of the His-tag, either to improve the biodistribution 
properties of the labelled protein48, 49 or to improve the labelling efficiency50-53 so that milder conditions can be employed and lower 
protein quantities can be labelled without need for the purification step (usually size-exclusion chromatography) which is usually a 
part of the process (Fig. 9). Incorporation of positively charged residues, and/or methionine or cysteine, adjacent to the His-tag 
sequence resulted in almost an order of magnitude increase in labelling efficiency when conjugating in phosphate buffers, for reasons 
that are yet to be elucidated.53 This shows that there are ways in which the properties and general utility of biomolecule labelling 
with 99mTc can be improved, and the further development of such methods to achieve a truly single-step, kit-based radiolabelling 
method for biomolecules is still a challenge for chemists. 
 
 
Figure 9:  Optimisation of His-tag sequences for 99mTc tricarbonyl labelling from high throughput screening. Top: relative labelling efficiency of a range of peptides. 
Purple symbols represent His-tags with adjacent arginine or lysine residues (i.e. positively charged sequences). Other colours represent uncharged and negatively 
charged sequences. Bottom: Comparison of labelling efficiency of optimal binding sequence selected from the screening (green)53 with established his tags sequences.48-
50 
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The Tc(V) nitride core,35 with the nitride ligand derived from hydrazine derivatives such as succinic dihydrazide, has recently been 
the subject of increased interest as a centre to which small molecules can be attached by means of dithiocarbamate ligands, a wide 
range of which can be easily synthesised by treatment of a primary or, preferably, secondary amine-containing molecule with carbon 
disulfide. This was first applied in the myocardial imaging agent 99mTc-NOET,54, 55 and more recently extended to other derivatives 
such as antibiotics, bisphosphonates and other drug-like molecules.56 In some circumstances the presence of two dithiocarbamate 
ligands offers, in theory, the opportunity to improve target affinity. An attempt to exploit this to develop improved agents for imaging 
bone disease and small soft-tissue calcifications produced a bis(bisphosphonate) derivative (Fig. 10) with two pendant 
bisphosphonate groups) which shows higher in vivo stability than 99mTc-MDP and is able to image vascular calcification in small 
animal models. However, the extent to which it can improve on molecules containing just one pendant bisphosphonate group (such 
as the tricarbonyl derivative, Fig. 11), or even 99mTc-MDP, is as yet unproven. New synthetic precursors from which the nitride-
ligand may derived have been developed recently, for both technetium and rhenium.57 
 
The arrival of combined modality imaging incorporating radionuclide and magnetic resonance contrast, to exploit simultaneously 
the advantages of each, has created interest in developing contrast agents that support both modalities in a single species. An 
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attractive clinical use is sentinel lymph node imaging, where surgeons value both pre-surgical imaging (SPET to identify a location 
and MRI to provide soft tissue contrast and fine structural detail) to identify lymph nodes draining tumours prior to surgery, and 
fluorescent contrast as a guide during surgery (Fig. 11). Several versions of iron oxide nanoparticles derivatised with radionuclides 
for such purposes have been reported, including materials with 99mTc linked to the nanoparticle using the tricarbonyl core directly58, 
59 or via a bisphosphonate linker60 (Fig. 11); the latter provides greatly improved stability compared to the conventional carboxylate 
linker used to anchor various modifiers to the surface of iron oxides. 
 
 
Figure 10:  SPET images (maximum intensity projection) of vascular calcification in a mouse model 30 min after injection with [99mTc]-MDP, [99mTc]-27 and [99mTc]-26. 
Arrows indicate uptake in calcified mesenteric arteries. Uptake in bone and clearance via kidneys and bladder is also evident. 
 
 
 
 
 
Beta-emitting isotopes rhenium-186 (b-, 92.5%, half-life 90 h) and rhenium-188 (b-, 100%, half-life 17 h) have been of interest to 
researchers for many years as therapeutic analogues of 99mTc radiopharmaceuticals. However, while other beta emitters such as 
yttrium-90 and lutetium-177 have become established in clinical use, so far rhenium isotopes have not made their presence felt 
widely in the clinic despite the convenience of the 188W/188Re generator, which is chemically analogous to the 99mTc generator. The 
chemical analogy between rhenium and technetium, which is often the basis of a diagnostic/therapeutic “matched pair” plan, must 
be implemented with caution61 since, when the ligand and core choice is not optimal to create thermodynamically and kinetically 
stable complexes with strongly preferred geometry and oxidation state, the structures, reactivity and biological behaviour may differ. 
The bisphosphonate complexes of technetium and rhenium, for example, behave very differently.62 On the other hand the tricarbonyl 
complexes, M(V) nitride-dithiocarbamate complexes and M(V) oxo-complexes (including those of MAG3, DMSA63 and 
tetraamines), are closely similar in structure and reactivity when M = Tc or Re, although they may require different synthesis 
conditions. The tricarbonyl core, in particular provides a highly stable and reliable means of synthesising structurally analogous 
protein and peptide conjugates64 via the His-tag coordination chemistry described above for 99mTc, and indeed the improvements in 
labelling efficiency shown in Fig. 9 apply equally to 188Re. There is thus every prospect that high quality 188Re radiopharmaceuticals 
could be developed for routine therapeutic use to exploit the convenience and potential cost-effectiveness of the 188Re-generator, if 
an appropriate business model can be identified.  
 
Figure 11:  Dual-modality (MRI/SPET) contrast agent combining iron oxide nanoparticles with 99mTc radiolabel linked to the inorganic iron oxide surface via 
bisphosphonate groups. Top: assembly of composite particle; bottom: Mouse images, transverse sections through liver. A: MR image pre-injection of contrast agent; B: 
MR image post-injection of contrast agent showing darkening of liver due to accumulation of iron oxide nanoparticles; C: SPET/CT image showing co-localisation of 
99mTc with iron oxide contrast in liver (L) and spleen (S). 
MDP$ 27$ 26$
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Group 8 
Iron-52 is a positron emitter (b+, 55.5%, half-life 8.28 h) but has no advantages for general clinical use and is of interest mainly as a 
tracer for investigating iron metabolism and distribution in health and disease in vivo.65, 66 Even this application is complicated by 
the fact that its decay leads to manganese-52m, which is also a positron emitter (b+, 98.3%, half-life 21.1 min) so it is not possible 
to know that PET images reflect iron distribution rather than the redistribution of the decay product 52mMn. This decay scheme can 
however be used as the basis of a generator system for producing the short half-life 52mMn27 (see Group 7). 
 
Ruthenium-97 has attractive gamma emission properties (g, 85%, half-life 2.9 days) that would make it suitable as a radiolabel for 
biomolecules with slow pharmacokinetics (i.e. applications similar to indium-111, see Group 13) but its production demands very 
high energy proton bombardment, limiting its availability and preventing general clinical development.67 
Group 9 
!
!
[99mTc]-27 
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Cobalt-55 (b+, 76%, half-life 17.5 h), as unchelated Co2+, is believed to mimic transport of calcium ions and has found applications 
in imaging tissue damage especially in brain, e.g. in stroke and vascular dementia.68 Its long half-life allows time for radiosynthesis 
to incorporate the isotope into structurally diverse targeting molecules, but this has been barely exploited.69 Efforts to label cells for 
in vivo cell tracking have been largely unsuccessful.70 
 
Rhodium-105 (b-, 100%, half-life 1.47 days) is a beta-emitter with potential applications in radionuclide therapy. Various 
bifunctional chelator systems based on combinations of soft donor groups (amine, thioether and phosphine) have been evaluated 
with some promise but have not yet translated into therapeutic evaluation.71-73   
Group 10 
Nickel-57 (b+, 43.4%, half-life 35.6 h) has been briefly explored as a PET imaging radiolabel but its use has been limited to labelling 
of metal chelating drugs (doxorubicin)74 and use in studying the toxicology of nickel itself.75  
 
Platinum-195m (g, half-life 4 days) is a reactor-produced radionuclide that emits low-abundance gamma photons. It has been used 
primarily for studying the biodistribution and pharmacokinetics of platinum anticancer drugs,59 and also experimentally as a 
radionuclide therapy by virtue of its Auger electron emissions.76  
Group 11 
Copper radioisotopes have made a major impact in the last two decades due to a combination of a versatile range of radionuclides 
for both imaging and therapy (Table 1), and chemical properties that are amenable to various imaging applications.77, 78 These 
properties include the kinetic stability of well-designed macrocyclic chelates,79, 80 suitable for labelling peptides and antibodies; well-
defined redox properties, especially bioreduction from Cu(II) to Cu(I), that lead to applications in blood flow and hypoxia imaging;81, 
82 and studies of the innate biological handling of copper and abnormalities in these processes associated with disease.83 A range of 
isotopes for PET imaging is available, with half-lives ranging from 9 minutes (62Cu, generator-produced) to 12.7 h (64Cu, cyclotron-
produced). In addition, 64Cu (which is a beta- and Auger electron-emitter as well as a positron emitter) and 67Cu (which combines 
beta and imageable gamma emissions) are attractive as therapeutic radionuclides. Despite early promise in clinical trials with 67Cu-
labelled antibodies, therapeutic application of 67Cu has not lived up to expectations because of lack of a reliable and cost-effective 
production route, which remains unresolved. 
 
Table 1:  Copper radioisotopes available for PET and radionuclide therapy. EC = electron capture. 
Isotope b %, Eave b+, %, Eave other t1/2 
Cu-60  93%, 0.87 MeV EC 24 min 
Cu-61  62%, 0.53 MeV EC 3.33 h 
Cu-62  98%, 1.32 MeV EC 9.75 min 
Cu-64 39%, 0.19 MeV 18%, 0.28 MeV EC 12.7 h 
Cu-67 100%, 0.12 MeV  g, 93 KeV, 52% 62 h 
 
 
 
 
Because of the attractive applications of the longer half-life isotopes 64Cu (PET imaging and radionuclide therapy) and 67Cu 
(radionuclide therapy and gamma imaging), many studies over the years have been devoted to identifying the best chelators for 
copper; some of the more significant ones are shown in Fig. 4; some more specific to copper are shown in Fig. 12. Early studies 
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favoured macrocyclic ligands TETA (Fig. 12) and cyclam,77 but with more experience DOTA, and most recently NOTA (5, Fig. 4) 
and the sarcophagine bicyclic structures84-86 (Fig. 12) have emerged as the leading chelators combining both high in vivo kinetic 
stability and high labelling efficiency at low chelator-antibody conjugate concentration under mild conditions.87 Non-macrocyclic 
ligands are consistently inferior, and cross-bridged cyclams (Fig. 12) other than the sarcophagines, designed to impart kinetic 
stability by virtue of the greater rigidity imparted by the cross-bridge, are still being evaluated.88, 89 In general, cross-bridging leads 
to greater kinetic stability, but also to a higher activation energy barrier to complex formation, leading to slower labelling and a 
requirement for harsher conditions. The sarcophagine ligands appear to represent an appropriate balance between these two effects. 
Despite the effective labelling and good stability in blood shown by antibodies labelled with 64Cu via NOTA and DOTA derivatives, 
a comparison of peptides labelled with 64Cu, 68Ga and 111In via these ligands suggested that dissociation of copper from the chelator, 
once the conjugate enters cells, leads to translocation of 64Cu to liver and hence to gut. This does not occur for the 111In and 68Ga 
labelled conjugates, indicating that these ligands remain far from optimal for tracking biomolecules with 64Cu.90 The design of 
bifunctional chelators for copper remains a highly active area. 
 
Figure 12:  Selection of chelators for radioisotopes of Cu2+; others of significance include 1 and 5 from Fig. 4.  
 
 
 
 
 
The redox properties of copper can be exploited in several different ways and for different purposes in diagnostic imaging. The 
common putative mechanistic theme in all these applications is that lipophilic Cu(II) complexes of bis(thiosemicarbazone) ligands 
(Fig. 13) diffuse into cells non-specifically, whereupon they are exposed to intracellular reducing agents causing reduction to Cu(I). 
The complexes may then dissociate either slowly (in the case of ATSM and related complexes with two backbone alkyl groups) or 
quickly (PTSM, GTSM and other complexes with <2 backbone alkyl groups). Once liberated from the ligand, the copper becomes 
subject to the cellular processes involved in tight regulation of intracellular copper, leading to incorporation into proteins or efflux 
from the cell, depending on the cell type. The slowly-dissociating complexes can be re-oxidised by molecular oxygen in the cell, 
whereupon they may escape by diffusing out, as the concentration gradient that drove them in is reversed by clearance from blood 
and excretion. This is the hypothetical basis of selectivity for hypoxic cells in CuATSM and related complexes,91-94 although other 
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factors also appear to control the cellular uptake and in vivo biodistribution of copper administered in the form of CuATSM.95-98 The 
rapidly-dissociating complexes, on the other hand, show no selectivity and deposit copper in cells and tissues in proportion to their 
delivery via blood, hence they are effectively blood flow imaging agents.  
 
This non-specific trapping has been put to use in cell labelling with 64CuPTSM99, 100 and 64CuGTSM, both of which show extremely 
efficient uptake and initial trapping in cells.101 Lipophilic 64Cu(dithiocarbamate) complexes behave similarly.101 However, cell 
tracking over the period of days allowed by the half-life of 64Cu is not effective because the copper-regulating processes cause efflux 
of copper over a period of several hours.101 To an extent this problem might be overcome by prior treatment of cells with chelating 
agents that will sequester 64Cu released inside the cell, preventing their transport out by specific cellular transport mechanisms.102 
This approach deserves further evaluation, since cell tracking with 64Cu is an attractive application because of the high-resolution 
PET imaging achievable with 64Cu. 
 
Non-specific trapping of CuPTSM and particularly CuGTSM is also being used as a basis for imaging biological transport processes 
for copper. Thus, 64CuGTSM can efficiently deliver 64Cu across the blood brain barrier and release it into cells (in contrast to, for 
example, CuATS which does not cross the blood brain barrier103). The resulting intracellular deposition of copper is sufficient to 
monitor the fate of the copper as it is exported from cells and redistributed; ionic 64Cu (e.g. Cu(acetate)2), on the other hand, does 
not enter cells and tissues in sufficient quantitities for this to be possible, and uptake in tissues reflects entry of copper into cells via 
specific transport systems. Thus, both delivery/influx and efflux mechanisms can be imaged separately. This can be applied to 
imaging changes (and early indications indicate that there are indeed imageable changes) in copper homeostasis and transport 
associated with disease, including Alzheimer’s disease104, 105 and other dementias, Menkes’ disease, and Wilson’s disease,83  and 
their treatment with copper-chelating drugs. Recent observations of uptake of 64Cu administered as ionic copper in tumours, 
including changes in uptake due to hypoxia, indicate that there are some interesting applications of tracking copper metabolism in 
tumours as well.95, 106 The full potential for imaging changes in copper metabolism to diagnose disease is only just beginning to 
dawn, and this represents a big opportunity and challenge for metals in imaging over the next few years.  
 
Hypoxia imaging with CuATSM is an important application, as hypoxia is a prognostic factor for response of tumours to radiotherapy 
and there are many other clinical indications for hypoxia measurement. It has been a subject of controversy recently because of 
observations that ionic 64Cu shows a biodistribution that is similar to that of 64CuATSM, including in some tumours studied.95 This 
is compounded by the likely mechanism, which entails dissociation and hence rapid release of free copper, resulting in potential 
supposition that 64Cu distribution after administration of 64CuATSM reflects distribution of ionic copper rather than hypoxia, and 
that in some tumours uptake of ionic copper may be related to hypoxia as well. These questions certainly complicate the interpretation 
of the 64CuATSM scans. However, Cu bis(thiosemicarbazone) complexes do not behave like unchelated copper in the early phase 
of biodistribution; CuATSM is hypoxia-selective, CuPTSM is (almost) not;92, 107 CuGTSM is taken up in normal myocardium, 
CuATSM is not;105 CuATSM and CuGTSM cross the blood brain barrier, CuATS and ionic copper do not.103 These differences are 
evident from Fig. 13. The most likely underlying mechanism is that all the complexes are, to a large extent, quickly metabolised in 
liver, releasing copper, part of which is excreted into the gut via the bile, and part of which is recirculated as copper transport proteins, 
leading to delayed uptake in tissues by specific copper transport mechanisms, which may themselves be disturbed in tumours and in 
hypoxic tissues. Since the clearance of CuATSM from non-hypoxic tissues is relatively quick, imaging can be performed early (e.g. 
20 min), as in most studies in Japan (where the short lived isotope 62Cu is most often used). New, less lipophilic analogues of 
CuATSM (e.g. CuATS and CuCTS, Fig. 13) show promise as potential superior replacements for CuATSM; they clear more quickly 
from normoxic tissue and reach higher hypoxic:normoxic tissue ratios in isolated rat hearts in a shorter time.107 In vivo evaluation of 
these compounds is anticipated with interest. 
 
Figure 13:  Structures of copper bis(thiosemicarbazone) complexes and PET imaging with 64Cu and its bis(thiosemicarbazone) complexes in mice 30 min post injection. 
Cu-acetate is rapidly taken up in liver and excreted into the gut; CuATSM (hypoxia-selective tracer) behaves in a superficially similar way; CuGTSM (non-hypoxia-selective 
tracer) likewise shows liver and gut activity but also shows high uptake in normal brain and myocardium.  
Dalton Discussions PREPRINT 
This journal is © The Royal Society of Chemistry 2014 Dalton Discussion XX | 20  
 
 
 
 
Much of the clinical work with CuATSM, especially in Japan, has been done with 62Cu. A 62Cu generator is not commercially 
available in Europe and very little work with 62Cu has been reported outside Japan.108 For clinical trials its short half-life (9 min) has 
the advantage of offering the opportunity to perform repeat scans with and without an intervention (e.g. oxygen breathing), with the 
patient in the same position on the scanner. For such purposes a 62Zn/62Cu generator has been implemented at King’s College London 
by means of a collaboration in which natural copper is irradiated using the cyclotron at the University of Birmingham, and the 
resulting 62Zn is processed to fabricate the generator at King’s. Fast chemistry for synthesis of 62CuATSM (to GMP standards) and 
other bis(thiosemicarbazone) complexes has been developed by implementing the solid phase transmetallation method reported by 
Dilworth et al.109 whereby the ligand, in the form of a zinc complex, is linked to a solid phase via a pyridine ligand, which binds an 
axial site of zinc. Passage of 62Cu solution over this stationary phase allows transmetallation to form the copper complex, releasing 
the ligand from the column and providing a product very quickly and with very high specific activity. This opens the door to several 
interesting clinical trials with very low radiation doses to patients. 
 
Because of its half-life, availability and excellent PET imaging properties, 64Cu has been a radioisotope of choice in radiolabelling 
nanoparticulate materials110-112 to assess drug delivery and combine imaging modalities. An example of the latter is radiolabelling 
of magnetic iron oxide nanoparticulate contrast agents with 64Cu using the bis(dithiocarbamate-bisphosphonate) complex shown in 
Fig. 14, in which the bisphosphonate groups anchor the 64Cu to the inorganic particle surface, allowing the potential of the new 
generation of PET/MRI scanners to be applied, for example, to sentinel lymph node localisation.113 
 
Figure 14:  Dual modality (PET/MR) imaging of sentinel lymph nodes in mice. A: assembly of 64Cu-labelled iron oxide/dextran nanoparticles using a dithiocarbamate- 
bisphosphonate ligand (as used in technetium complex 26, see Fig. 10). B: MR scan (coronal section) of hind limbs and lower abdomen, pre-injection of contrast agent. 
Lymph nodes are visible as bright areas (arrow). C: MR scan post-injection of contrast agent, showing darkening of lymph nodes due to uptake of MR contrast. D: PET/CT 
scan showing radioactivity co-localised with magnetic particles (arrows). The radioactivity remains bound to the magnetic particles in vivo. 
Cu-acetate CuATSM CuGTSM 
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Other Group 11 metallic isotopes of interest to molecular targeting include 111Ag114 and 198Au115 (beta-emitters with potential, if  not 
yet actual, application in targeted radionuclide therapy).  
 
Group 12 
62Zn is important as the parent isotope in the 62Zn/62Cu generator (see Group 11). 197Hg-chlormerodrin116 (g, 100%, half-life 64.14 
h) was used in the early days of nuclear medicine as a renal perfusion agent before replacement with 99mTc tracers. 197Hg can be 
coupled to biomolecules using a bifunctional chelator incorporating the soft macrocyclic ligand 1,4,7-trithiacyclonane.117 
Group 13 
Group 13 is a feast for the radiometal molecular imager. Gallium, indium and thallium have radionuclides of great historic and 
current importance, and even boron and aluminium, while offering no useful radionuclides, have come to prominence very recently 
because of their role as inorganic binding sites for the important radionuclide fluorine-18, a role which will be discussed under Group 
17. 
 
Gallium-67 (g, 86%, half-life 3.26 days) has been important in nuclear medicine for decades. Among the various applications and 
complexes explored are two main clinical roles: imaging of lymphoma and other tumours,118, 119 and imaging of infection.120 Uptake 
in lymphoma is believed to be mediated by transferrin receptors, taking advantage of the serum speciation of gallium when 
administered as the citrate complex, which involves a significant fraction of the radionuclide binding to the iron-binding sites of the 
iron transport protein transferrin (reliable experimental evidence for this mechanism, however, is hard to pin down in the 
literature).121 The clearance of radioactivity from blood is very slow, resulting in delays of several days before useful imaging can 
be performed, making the long half-life of 67Ga essential to this application. The mechanism by which 67Ga (again administered as 
citrate complex) is accumulated in sites of infection is unclear and may be related either to targeting of the infiltrating immune cells, 
or targeting the microorganisms themselves, by binding to secreted polysaccharides or by transchelation to bacterial siderophores 
followed by siderophore-mediated uptake into the bacterial (or fungal) cells. Thus, these applications might rely fundamentally on 
the biological mimicry of iron by gallium. 
!
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A newly-emerging potential role for 67Ga arises from the Auger electron emissions that accompany its nuclear decay, offering 
possible application as a therapeutic radionuclide. These electrons are higher in number and energy than some other Auger electron 
emitters, leading to substantial local radiation dose to the individual cells in which the 67Ga is located. The higher energy means that 
the radionuclide may not need to be located within the cell nucleus in order to have DNA damaging effects. Early indications 
supported the idea that 67Ga may be more cytotoxic than 111In which has previously been evaluated as a radionuclide therapy agent 
in clinical trials.122-127 The radiobiological effects of intracellular 67Ga on cell survival warrant further study, in light of recent 
improvements in chelation and delivery of gallium isotopes.  
 
68Ga (b+, 88.9%, half-life 68 min) is set to make an impact on PET imaging comparable to that made by 99mTc half a century ago. It 
is a generator produced positron-emitting isotope with a half-life of 68 min – long enough for reasonably quick radiolabelling 
chemistry and for biodistribution of most small molecules, peptides etc., but short enough to keep radiation doses reasonably low. 
Despite commercial generators with marketing authorisation not having been available, many centres, especially in Europe, have 
been using 68Ga clinically, mainly in the context of somatostatin receptor-targeting peptides such as DOTATATE, DOTATOC and 
analogues,128, 129 to which the radiometal is attached via a DOTA chelator (Fig. 4). Many of the technical issues that have delayed 
the regulatory approval of the generator have now been overcome and in 2014, the first marketing authorisation for a 68Ge/68Ga 
generator was granted by the EMEA and clinical use of 68Ga is likely to spread and increase greatly, creating a second revolution in 
clinical PET (the first being the spread of cyclotrons and PET scanners driven by the enormous clinical utility of 18F-
fluorodeoxyglucose) by making it available in centres that do not have a cyclotron nearby. One might provoke a lively discussion 
by observing that this development coincides with the current (and probably future) era of shortages of 99mTc, and could be a factor 
that informs decisions about the future of 99mTc as the workhorse of nuclear medicine (see Group 7). The arrival of the generator has 
sparked a proliferation of new 68Ga imaging agents, particularly biomolecules such as peptides and small proteins, and conjugates 
of small molecules such as bisphosphonates130, 131 and folic acid,132, 133 to make economic use of the generator to bring its benefits 
to the maximum number of patients world wide. The development of new agents, and in particular their widespread application, 
requires radiolabelling chemistry that can be performed quickly, with the minimum of manipulation and the minimum of costly 
equipment, on the hospital premises. That is, labelling methodology akin to the 99mTc labelling kits that made radiopharmaceuticals 
available at low cost, that can be performed in facilities little more complex than conventional hospital radiopharmacies rather than 
PET radiochemistry centres with cyclotrons and arrays of robotic synthesisers and hot cells.  
 
Despite having become the standard bifunctional chelator used in the first wave of 68Ga-labelled peptides, DOTA (Fig. 4) was not 
designed specifically for Ga3+ chelation and is not ideal because labelling it requires relatively harsh conditions – heat (e.g. 90oC), 
time (30 min) and low pH, all of which bring inconvenience and undesirable complexity and may be incompatible with the 
biomolecule concerned. The last few years has seen something of a “beauty pageant” of new bifunctional chelators for 68Ga, aiming 
to improve the labelling conditions and efficiency while maintaining adequate in vivo stability. A selection is shown in Fig. 4; a 
more comprehensive selection is discussed in an excellent recent review of metal chelators for radionuclides.7, 134 Many of these 
ligands, such as HBED (6, Fig. 4), DEDPA (7) and TRAP (8), significantly improve the labelling conditions compared to DOTA, 
and have good biostability and other potential advantages. Indeed HBED is the basis of very promising 68Ga-bioconjugates (e.g. the 
PSMA ligand for imaging prostate cancer) now being used in the clinic.135 For rapid labelling under the mildest conditions at the 
lowest concentrations, the acyclic tripodal  tris(hydroxypyridinone) ligand CP256, and its bifunctional conjugate YM103 (4, Fig. 4), 
appear to be the optimal choice, based on direct side-by-side comparison with some of the other ligands. Its design was based on the 
premise that rapid, mild and efficient labelling overrides in vivo stability as an important feature, because of the short half-life. The 
immediate future promises rapid development in this field and a small number of purpose-designed gallium chelators will soon 
emerge as a basis for commercial development of kit-based 68Ga labelled radiopharmaceuticals. 
 
A surprising property of YM103 is its ability to transchelate 68Ga bound to transferrin in serum. This has been demonstrated in vitro 
by incubating in serum.19 The extent to which other chelators can do this has not been established but it raises the intriguing 
possibility of radiolabelling in vivo. This has been demonstrated by injecting 68Ga acetate into mice, observing the typical slow 
clearance from blood to bone, and following with an injection of CP256 whereupon the circulating 68Ga is immediately cleared from 
the circulation and excreted via the kidney (Fig. 15). Such behaviour, on a longer timescale, has been demonstrated previously for 
DFO using 67Ga.136, 137 This in vivo transchelation is being explored as a basis for pretargeting with antibodies: injection of an 
antibody-YM103 conjugate, followed after a suitable period to allow targeting by an injection of 68Ga-acetate. The pre-injected 
antibody perturbed the biodistribution of the 68Ga, increasing its uptake in the tissues targeted by he antibody. This observation 
indicates potential for a new form of pre-targeting based on in vivo metal transchelation,138 allowing use of short half-life 
radioisotopes such as 68Ga even with targeting biomolecules that have very slow pharmacokinetics. 
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Figure 15:  A. Concept of pre-targeting by in vivo transchelation of 68Ga, which is feasible with YM103 (4 in Fig. 4) because of its ability to transchelate Ga3+ from 
transferrin in plasma and in vivo. Inset: Uptake of 68Ga in most organs (including spleen which is the location of the macrophages expressing sialoadhesin, the SER4 
antibody target) when given as a chase after administration of antibody-YM103 conjugate, is intermediate between that of the pre-labelled antibody and the distribution 
of 68Ga given as a chase after administration of unconjugated antibody. The exception is bone, which is the target of unchelated 68Ga (see part B, left image). This 
suggests that 68Ga is able to find and bind to the pre-targeted antibody-YM103 conjugate in vivo. B: Demonstration that the tris(hydroxypyridinone) chelator CP256 
(non-derivatised form of YM103) can bind to 68Ga in vivo and excrete it rapidly via kidney. Left: Biodistribution of 68Ga administered in unchelated form; centre and 
right: biodistribution of 68Ga-CP256 complex 1 min and 30 min post-injection respectively, showing rapid renal excretion in progress and completed. Similar images are 
obtained if the 68Ga is administered first, followed by the CP256 ligand.  
 
 
 
 
The similarity in ligand donor and geometric preferences between Ga(III) and Fe(III) underlies a new application of molecular 
imaging that is specific to gallium: species-specific imaging of microbial infection (bacterial or fungal) using 68Ga-labelled 
siderophores. This exploits the microorganisms’ highly developed systems for acquiring iron from their environment, in which they 
secrete low molecular weight chelators (siderophores) which bind Fe(III) with extremely high affinity, and then take up the 
complexes via specific transporters. By labelling these molecules with 68Ga in place of iron, the structural analogy of the complex 
is adequate for the Ga complex to be taken up by the siderophore receptor, allowing this molecular mechanism to be used for specific 
imaging of the presence of the living microorganisms in vivo. This has been applied to detect Aspergillus fumigatus infection using 
its specific sidrerophores desferri-triacetylfusarinine C (TAFC) and desferri-ferricrocin (FC) (Fig. 16), and similarly other 
microbe/siderophore combinations, in animal models.139-142 This represents a highly promising new area for development. 
 
Figure 16:  Siderophores labelled with 68Ga for targeting microorganisms: TAFC = triacetylfusarinine; FOXE = ferrixoamine E; FC = desferriferricrocin. 
Model system: Ser4 monoclonal  antibody binds to Sialoadhesin on pro-
inflammatory macrophages, hence targets liver, spleen and bone marrow. 
The antibody-YM103 conjugate is injected and chased by Ga67/68 citrate. 
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Indium-111 (g, 100%, half-life 2.8 days) was the first radionuclide to be commercially and clinically established in routine practice 
in gamma imaging applications that necessitate a long half-life: labelling monoclonal antibodies and labelling cells. Its commercial 
development in the 1980’s coincided with the emergence of monoclonal antibody technology, which underpinned hopes of “magic 
bullet” drugs and diagnostics. It forms reasonably stable chelates with various polyaminocarboxylates and unlike copper it does not 
appear to be essential to use a macocyclic chelator for 111In. Even the prototype DTPA (9, Fig. 4), coupled to antibodies by reaction 
of its cyclic anhydride with amine side chains of lysine residues, provided excellent results in the early days of antibody imaging, 
and was the chelator employed in the first commercially available peptide-based imaging agent Octreoscan.143 DTPA has since been 
supplanted by related ligands (Fig. 4) offering greater kinetic inertness through incorporation of cross-bridging, backbone alkylation 
and cyclisation, e.g. DOTA144 or CHX-A’’-DTPA145. 111In remains the most important gamma-emitting radiolabel for antibodies 
(see for example Fig. 17).  
 
Figure 17:  Typical tumour SPET/CT imaging with whole IgG monoclonal antibody in mouse bearing an experimental melanoma on the flank, illustrating the need for 
long half-life radionuclide (in this case 111In, half-life 2.8 days).  CSPG4 IgG antibody, which binds to melanoma associated antigen, was labelled with 111In using the 
bifunctional chelator CHX-A’’-DTPA. Images show predominantly blood pool at 4 h (A) and 24 h (B) with increasing tumour- and spleen-to-blood ratio 48 h and optimal 
images are not seen until 48-120 h.  
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Cell labelling with 111In, developed to allow clinical imaging and localisation of infection and inflammation sites, was first developed 
in the late 1970s and entered widespread clinical use in the 1980s. The design principle was the opposite of that required in antibody 
labelling – rather than kinetic stability the aim was to form biologically unstable lipophilic complexes able to diffuse into cells and 
dissociate when exposed to the intracellular milieu. This was achieved with a number of uninegative bidentate ligands such as oxinate 
and tropolonate, forming InL3 complexes (Fig. 7) and these complexes remain in demand for imaging inflammation and infection.146 
The rise of cellular therapies (transplants, stem cells etc.) has created new applications for cell tracking and 111In is likely to continue 
to fill this need for some time to come.  
 
Thallium-201 (g, 10%, half-life 73 h), in the form of thallium(I) chloride, was the first routinely used myocardial perfusion imaging 
agent. Since it became established in clinical use it has become recognised that the 201Tl+ cation, like rubidium discussed earlier, is 
a potassium mimic and a substrate of the sodium/potassium ATPase and so, like 82Rb+, is efficiently taken up in well-perfused 
myocardium.147 Despite its low g-yield (which is compensated by a higher abundance of X-ray emissions) it remained the regular 
clinical myocardial imaging agent until supplanted by the lipophilic cationic technetium complexes, and made something of a come-
back during recent 99mTc shortages. Its cationic charge was, misguidedly but ultimately successfully, the design template148 for these 
hugely commercially successful new 99mTc myocardial agents developed in the 1980s; these are in fact not potassium mimics but 
are trapped in mitochondria by virtue of their cationic charge, and access them by virtue of their lipophilicity.149 201Tl has been (and 
is in many centres) also used to detect tumours, being taken up presumably by the same mechanism. 
Group 14 
Group 14 offers carbon-11 (b+, 99.6%, half-life 20 min). This radioisotope makes possible the labelling of organic compounds 
without structural modification and provides a role for synthetic organic chemists in molecular imaging, which is outside the scope 
of this Perspective. In this field there is no escaping the dependence on a local cyclotron, automated multi-step synthesis and 
purification and so the challenges are rather different to those of inorganic radiochemistry. Other contributions from Group 14 
include tin-117m (g, 86%, and conversion electron emitter, half-life 13.6 days) which, as its Sn(IV) DTPA complex, shows exquisite 
selectivity for bone metastases, where its very short range electron emissions keep bone normal marrow irradiation to a minimum.150 
Despite this advantage it has not become established as a widely-used bone therapy agent, possibly because of limitations on the 
scale of production. Lead-212 (b-, 100%, half-life 10.6 h) is of interest as an “in vivo generator” of the alpha-emitter bismuth-212. 
The in vivo generator principle poses the additional challenge that the energetic decay process of the parent isotope (recoil energy 
and shower of conversion or Auger electrons) can induce dissociation, and the chelating system must be able to resist this or allow 
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rapid reassociation with the daughter nuclide. Macrocyclic polyaminocarboxlyate chelators, particularly DOTA (Fig. 4) show 
efficacy as bifunctional chelators of Pb2+ but it has been shown that replacing the carboxylate groups with primary amides, giving 
an octadentate ligand TCMC (10, Fig. 4) which coordinates through the four amines and four carbonyl oxygens of the amide groups, 
is advantageous and in use in a clinical trial of 212Pb-labelled antibody.151-153  
Group 15 
Nitrogen-13 (b+, 99.8%, half life 10 min) is a very short-lived positron-emitting radionuclide most readily produced from cyclotrons 
in the form of ammonia or, less commonly, nitrate/nitrite. Its only established clinical application is use of 13NH3 as a myocardial 
perfusion PET imaging agent. The ubiquitous appearance of nitrogen in biomolecules, metabolites and drugs creates attractive 
applications based on incorporating 13N into more complex molecules, but this has been to all intents and purposes unrealised because 
of the perception that the half-life is too short for the relatively complex chemistry to be practicable. However, very recently the 
feasibility has been demonstrated to utilise 13NH3 as a precursors for more complex molecules,154, 155 opening a potential new field 
of organic PET radiochemistry. Inorganic applications might also be envisaged utilising the ability of ammonia to bind to metals. 
 
Phosphorus-32 (b-, 100%, half-life 14 days), a high-energy beta-emitter, is the oldest radionuclide used in nuclear medicine, having 
been evaluated in the 1930s in the form of phosphate for treatment of haematological disorders. It is still used for treatment of 
polycythemia vera. It has also been widely used for palliative therapy of bone metastases, since it targets areas of bone mineral 
deposition, but has fallen out of favour because of high bone marrow dose associated with uptake in rapidly dividing cells in bone 
marrow. Its complete lack of photoemission precludes reliable imaging. Lack of imageable emissions has not prevented widespread 
therapeutic use of other beta-emitters such as 90Y, however, and it is surprising that 32P has barely been used therapeutically in any 
chemically targeted form other than phosphate and polyphosphates (except radiolabelled colloids for topical application in tumours 
and arthritis). Given its relatively low cost and an amenable half-life, it is possible to imagine that useful agents could be developed 
by broadening the chemistry, perhaps to incorporate 32P into some of the many bisphosphonate drugs that are now widely used in 
treatment of bone diseases. The very few attempts to develop more complex targeted agents containing 32P include labelling of 
ATP156 and labelling of targeting proteins.157 33P (b-, 100%, half-life 25.3 days), a medium-energy beta-emitter, has been suggested 
as an alternative to 32P as a therapeutic radionuclide with lower energy beta emissions,158 but no biological or clinical evaluations 
have been reported to date. 
 
Arsenic has several positron emitting isotopes with potential for PET imaging including 71As (b+, 30%, half-life 64 h), 72As (b+, 
88%, half-life 26 h), and 74As (b+, 29%, half-life 17.8 days), and beta-emitting isotopes that in principle could be used for 
radionuclide therapy, including 77As (b-, 100%, half-life 38.8 h) and 76As (b-, 100%, half-life 26.3 h). The half-lives of all the positron 
emitters are compatible with use with antibody targeting. 72As can be produced from a generator (parent isotope 72Se)159 by eluting 
it in the form of arsenic triiodide AsI3, which can be covalently attached to antibodies modified to create thiol side chains, by 
elimination of HI with formation of arsenic-sulfur bonds.160 Although radionuclide imaging with 74As dates back to the 1950s,161 it 
has been explored surprisingly little to date. 
 
Bismuth-212 (a, 36%, b-, 64%, half-life 60.6 min) and bismuth-213 (complex decay chain involving alpha and beta emissions, half-
life 46 min) are alpha emitters. Their short half-lives are less than ideal for targeted radionuclide therapy but still, some targeting 
molecules may have sufficiently rapid target accumulation in vivo that they could be used. 213Bi is eluted from the 225Ac/213Bi 
generator and is readily chelated by DOTA derivatives for attachment to antibodies; applications are envisaged in diffuse cancers in 
which the radiopharmaceutical can easily access individual cancer cells (e.g. leukaemias),162 or possibly using a pre-targeting 
approach using 213Bi-conjugated biotin.163 212Bi will most likely find application in the form of the in vivo generator whereby 212Pb 
attached to a targeting molecule (see Group 14) decays in vivo to 212Bi, which, if the chelate withstands the decay process, remains 
in situ long enough to deliver its alpha particles to the target tissue.151-153 
Group 16 
The half-life of oxygen-15 (b+, 100%, half-life 2 min), which can be produced in cyclotrons in the form of H2O (used for blood flow 
quantification) or O2, is so short that even die-hards who consider 15N and 62Cu amenable to incorporation into targeting molecules 
draw the line at labelling complex molecules with it. Nevertheless CO, butanol and 2-deoxy-D-glucose have been labelled for 
potential in vivo applications.164  
Group 17 
Fluorine-18 (b+, 96.7%, half-life 20 min) is currently by far the most important radionuclide in PET, and is used most often in the 
form of [18F]-2-fluoro-2-deoxyglucose. By far the major route to incorporating it into targeting molecules is formation of carbon-
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fluorine bonds, which falls outside the scope of this inorganic Perspective. However, interest in the inorganic chemistry of fluorine, 
using elements other than carbon as a binding site for 18F, is growing. Since it has been reviewed recently165 it will be introduced 
here very briefly. Boron, aluminium and silicon, all of which have very high bond energy in binding with fluorine, have been the 
most studied. 18F-labelled aryl trifluoroborate (ArBF3-) and alkylfluorosilanes166, 167 have been used as prosthetic groups for labelling 
biomolecules, and the 18F-labelled tetrafluoroborate ion is, like iodide (vide infra) and pertechnetate, a substrate of the sodium/iodide 
symporter and is under development as a PET imaging agent for thyroid disease, with the potential to improve on the sensitivity of 
gamma camera and SPET imaging with [99mTc]-pertechnetate (Fig. 18).168, 169 Coordinatively unsaturated aluminium complexes 
based on bifunctional NOTA derivatives can be linked to biomolecules and will complex fluoride ions to produce stable 
radiopharmaceuticals. This is an exciting new area which has recently been reviewed.170, 171 With further development to introduce 
aluminium chelates that will bind fluoride under milder conditions and reach higher specific activity, it may have the potential to 
bring simple, one-step kit-like labelling chemistry to 18F labelling of biomolecules.  
 
Figure 18:  A. Nucleophilic radiolabelling of boronic ester prosthetic group; B: Isotopic exchange labelling of fluorosilane prosthetic group; C: Use of coordinatively 
unsaturated aluminium complex as a binding site for fluoride ions in biomolecule labelling; D: currently favoured ligand for chelation of Al3+ and labelling with [18F]-
fluoride; E: PET-CT imaging of sodium/iodide symporter (NIS) activity mouse using NIS substrate [18F}-BF4-, 30 min post-injection. Left: normal mouse showing thyroid 
and stomach uptake and excretion into bladder; Centre: mouse with implanted NIS-expressing breast tumour showing tumour (T) uptake as well as thyroid (Th) and 
stomach (S) uptake; right: normal mouse pre-injected with perchlorate to block NIS activity, showing radioactivity largely confined to blood pool. 
 
 
 
Bromine has positron emitting isotopes 75Br (half-life 96.7 min) and 76Br (half-life 16.2 h) that can usefully be incorporated into 
organic molecules, usually by formation of aromatic C-Br bonds using oxidative electrophilic bromination. Much of this chemistry 
is analogous to iodination chemistry referred to below. Despite the suitable emission properties of the isotopes they have not found 
wide use. The production and utility of these isotopes have been reviewed recently.172 
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Iodine isotopes are extremely versatile, both from a radiological and chemical perspective. Iodine-131 (b-, 91%, g, 82%, half-life 8.1 
days) is of great historical significance in nuclear medicine and was among the earliest isotopes used clinically, originally used 
primarily as a radionuclide therapy in thyroid disease and later, with the advent of imaging, as an imaging agent for “thyroid 
function”. Its half-life is suitable for therapy in this context but its imaging characteristics are not ideal and better images, with 
smaller radiation doses, were later accessible with the introduction of the gamma-emitter 123I (g, 83%, half-life 13 h). In the age of 
PET, iodine is represented by 124I (b+, 23%, half-life 4.2 days) which, despite less than ideal imaging properties and an unnecessarily 
long half-life, advances the sensitivity of imaging a step further compared to the gamma-emitting isotopes. As well as imaging 
“thyroid function” (later transforming into “molecular imaging” of sodium/iodide symporter activity once that transporter had been 
identified, cloned and characterised in the 1990s, nicely illustrating a semantic distinction between functional imaging and molecular 
imaging as different interpretations of the same imaging process in different eras), it is readily incorporated into organic and 
biological molecules, usually by formation of aromatic carbon-iodine bonds. In the case of proteins and peptides this is most often 
by electrophilic substitution in the activated aromatic groups of tyrosine side chains. The chemistry of incorporation of radioiodine 
into organic and biological molecules has been well-reviewed elsewhere.173-175 
 
Astatine-211 (a, 100%, half-life 7 h) is one of the prominent alpha-emitting radionuclides being evaluated for radionuclide therapy. 
It holds a fascination for many inorganic chemists, because, having no stable elements, its chemistry has barely been explored. Most 
of the chemistry for incorporating it into targeting molecules is based on an assumed analogy to iodine, with a tendency towards 
preferring higher oxidation states by comparison. Hence it is usually incorporated with reasonable stability into aromatic groups by 
C-At bond formation using electrophilic substitution.173 However, it has recently been the subject of interest from an inorganic 
perspective, on the one hand being treated as a metal to see whether chelating agents could bind it satisfactorily in its higher oxidation 
states, and on the other by exploring the coordination of astatide ions to the softer transition metals. These approaches are at the very 
early stages of evaluation and have not yet shown signs of replacing conventional organic astatine chemistry as the basis of 
radiolabelling.176-180  
Group 18 
Being “noble” the group 18 elements cannot be incorporated into targeting molecules but are useful in the form of the elemental gas 
for lung ventilation studies and perfusion of tissues, especially brain and liver. Gamma emitting members of the family are krypton-
81m (g, 68%, half-life 13 s)181 and xenon-133 (g, 37%, b-, 100%, half-life 5.24 days).29 The gaseous state is exploited in the design 
of the krypton-81m generator, from which the gas is eluted from a solid support with air directly into the inhaled airstream.  
Lanthanides 
The coordination preferences of the lanthanides bear similarity to the group 3 and group 13 metals, and all form 3+ cations that can 
be chelated with oxygen/nitrogen donor ligands, with maximum kinetic stability obtained using macrocyclic ligands, especially 
DOTA. Although all can be effectively bound by the same chelator, there is a contraction in ionic radius towards the right of the 
period (the “lanthanide contraction”), which affects the coordination number, potentially leading to variations in biological behaviour 
when bioconjugates with the same chelator are labelled with different metals. Most important are lutetium-177 (b-, 100%, g, 14%, 
half-life 6.65 days),10 samarium-153 (b-, 100%, g, 29.8%, half-life 46.27 h),182 holmium-166 (b-, 100%, half-life 1.12 days),183 and 
terbium-149 (a, 16.7%, b+, 83.3%, half-life 4.12 h),184 all of which are therapeutic isotopes and some of which can be imaged with 
a gamma or PET camera. The overlap in chemistry between the lanthanide elements and the group 3 and 13 metals is useful as a 
basis for multimodality imaging (aspects of which are discussed elsewhere in this issue), exploiting the luminescent properties of 
the elements for optical imaging, the high relaxivity of gadolinium complexes for magnetic resonance imaging, and the radionuclide 
properties of the lanthanides and chemically similar elements like 68Ga and 111In which can share the same chelators.  
Actinides 
Actinium-225 (a, complex decay chain, half-life 10.0 days) decays via a sequence of alpha-emissions and so imparts an 
extraordinarily high local radiation dose per atom, which can be exploited for targeted radionuclide therapy. Despite the large ionic 
radius, the well-established macrocyclic chelator DOTA is a satisfactory means for coupling Ac3+ to targeting molecules such as 
antibodies, and the DOTA complex is indeed more kinetically stable than complexes of related macrocyclic ligands of higher 
denticity.185 Thorium-227 (a, complex decay chain, half-life 18.5 days) also decays via a sequence of alpha-emissions, and is also 
adequately bound to antibodies by DOTA-based bifunctional chelators.186 These alpha-decay series elements are currently involved 
in a number of early-phase clinical trials with commercial sponsorship; it is a rapidly developing field, invigorated by the success of 
larger trials with 223Ra (see Group 2) in palliative treatment of bone metastases. 
Conclusion 
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Nuclear medicine and molecular imaging has provided a gratifying mix of inorganic chemistry challenges, multidisciplinary 
collaboration, and tangible benefits to patients, health services and business, making it a stimulating and hugely varied area in which 
to spend a career in inorganic chemistry and providing opportunities to apply chemistry not only from all areas of the periodic table, 
but different types of materials and molecules including organic molecules, metal chelates, proteins, peptides and nanoparticles. 
There have been significant developments recently in many of these areas, raising prospects for translation of new radionuclides and 
molecular imaging mechanisms, which in turn creates new inorganic chemical challenges. It will be interesting for inorganic 
chemists not only to observe the outcomes of their past developments for clinical applications and commercial products, but to drive 
them by providing new chemistry to improve the quality and accessibility of molecular imaging and radionuclide therapy for patients. 
Old challenges remain and new ones emerge across the periodic table. New non-cardiac applications should emerge for the 82Rb 
generator. The 68Ga generator is becoming established clinically as a source of positron emitting radiopharmaceuticals, with the 
possibility to revolutionise PET by making it available to centres without cyclotrons and complex radiochemistry facilities. To 
achieve this requires a shift in emphasis in chelator design from long-term kinetic stability towards rapid complexation under mild 
conditions and at very low concentration. New generator-produced medium-half-life positron emitting radionuclides such as 44Sc 
and 90Nb are emerging and may offer similar possibilities. All these isotopes require new chemistry for effective, and above all, 
simple incorporation into targeting molecules. Longer half life positron emitters such as 89Zr isotopes are already making an impact 
in imaging with antibodies in humans, and this impact may now spread to cell tracking. The growing availability and versatility of 
very short half-life (<20 min) positron emitters (13N, 62Cu, 82Rb, 15O, 52mMn) presents a new opportunity to perform multiple scans 
in individual patients to explore multiple facets of tissue physiology and gene expression in a single scanning session, without unduly 
high radiation doses; realisation of this possibility also creates needs and opportunities for innovative fast chemistry. The emergence 
of generator-produced positron emitters, and the closure of reactors producing 99Mo, threatens the position of 99mTc at the centre of 
radionuclide imaging, but a renaissance of 99mTc may follow if the production infrastructure becomes more secure. This will highlight 
a need for new technetium chemistry, particularly for convenient kit-based incorporation into biomolecules, which despite many 
years of research remains far from optimal and 99mTc has surrendered a lead to 68Ga in this respect. Copper radioisotopes continue 
to command very wide interest and there is a growing recognition of their potential in the study of copper biochemistry in health and 
disease, creating a major new field of activity in PET. The use of metals such as aluminium as binding sites for fluoride shows 
promise for easy incorporation of 18F into biomolecules but this has some way to go to achieve its potential; this approach could be 
extended to other metals and radiolabels. Finally, the clinical success with 223Ra radionuclide therapy may stimulate a resurgence of 
interest in radionuclide therapy, especially with alpha-emitting isotopes, e.g. of Bi, Ac, Th, Pb, At and Tb, whose coordination 
chemistry has yet to be optimised for the purpose, and of 223Ra which requires completely new thinking if it is to be incorporated 
into biological targeting molecules. There is something for everyone. 
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